Friday July 28, 2017 13:43

Heathcare Press Release : 01 Mar 2017

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Heathcare—01 Mar 17

- Prognosis for urothelial carcinoma is currently poor, particularly when the disease has metastasized Merck and Pfizer Inc. today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License